Teva Pharmaceutical Industries (TEVA -12.9%) commences the U.S. commercial launch of its generic version of Gilead Sciences’ (GILD -3.2%) angina med Ranexa (ranolazine) Extended-Release Tablets, 500 mg and 1,000 mg.
Pre IQVIA, the U.S. market is ~$938M.
TEVA is under pressure from its exposure to opioid marketing-related and generic drug price-fixing lawsuits.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.